
## Maria E Suarez-Almazor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/182408/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Systemic Lupus Erythematosus and Mortality in Elderly Patients With Early Breast Cancer. Arthritis Care and Research, 2023, 75, 559-568.	1.5	4
2	Patient perspectives on long-term outcomes in rheumatoid arthritis. A qualitative study from the OMERACT patient outcomes in longitudinal studies working group. Seminars in Arthritis and Rheumatism, 2023, 58, 152028.	1.6	1
3	Derivation and Validation of the Cancer READMIT Score: A Readmission Risk Scoring System for Patients With Solid Tumor Malignancies. JCO Oncology Practice, 2022, 18, e117-e128.	1.4	3
4	Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. Journal of Immunotherapy and Precision Oncology, 2022, 5, 26-30.	0.6	1
5	Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program. Pilot and Feasibility Studies, 2022, 8, 45.	0.5	3
6	Postoperative Major Adverse Cardiac Events in Patients With Systemic Lupus Erythematosus. ACR Open Rheumatology, 2022, , .	0.9	0
7	Exercise and physical therapy for systemic sclerosis. The Cochrane Library, 2022, 2022, .	1.5	0
8	Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications, 2022, 13, 1970.	5.8	34
9	A randomized controlled trial evaluating the effects of social networking on chronic disease management in rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2022, 56, 152072.	1.6	3
10	Treatment Sequences After Discontinuing a Tumor Necrosis Factor Inhibitor in Patients With Rheumatoid Arthritis: A Comparison of Cycling Versus Swapping Strategies. Arthritis Care and Research, 2021, 73, 1461-1469.	1.5	8
11	Randomized Controlled Trial of Patient Education Tools for Patients With Rheumatoid Arthritis. Arthritis Care and Research, 2021, 73, 1470-1478.	1.5	10
12	Outcomes Reported in Prospective Longâ€Term Observational Studies and Registries of Patients With Rheumatoid Arthritis Worldwide: An Outcome Measures in Rheumatology Systematic Review. Arthritis Care and Research, 2021, 73, 649-657.	1.5	6
13	Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors. Arthritis and Rheumatology, 2021, 73, 866-874.	2.9	56
14	Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 73-83.	0.5	3
15	A Randomized Controlled Trial Comparing Two Selfâ€Administered Educational Strategies for Patients With Knee Osteoarthritis. ACR Open Rheumatology, 2021, 3, 185-195.	0.9	2
16	Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation. , 2021, 9, e001818.		14
17	Quality appraisal of educational websites about osteoporosis and bone health. Archives of Osteoporosis, 2021, 16, 28.	1.0	1
18	Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis. Immunotherapy, 2021, 13, 465-475.	1.0	9

#	Article	IF	CITATIONS
19	Reply. Arthritis and Rheumatology, 2021, 73, 1564-1564.	2.9	Ο
20	Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. Seminars in Arthritis and Rheumatism, 2021, 51, 593-600.	1.6	13
21	Guest Editors' Introduction. Journal of the National Cancer Institute Monographs, 2021, 2021, 1-2.	0.9	0
22	Launching an Electronic Patient-Reported Outcomes Initiative in Real-Time Clinical Practice. Journal of the National Cancer Institute Monographs, 2021, 2021, 23-30.	0.9	4
23	Development of a patient-centered core domain set for prospective observational longitudinal outcome studies in rheumatoid arthritis: an OMERACT initiative. Seminars in Arthritis and Rheumatism, 2021, 51, 1113-1116.	1.6	4
24	Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitors. Cancer Immunology, Immunotherapy, 2021, 70, 1939-1949.	2.0	27
25	Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. Journal of Clinical Oncology, 2021, 39, 3978-3992.	0.8	121
26	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 4073-4126.	0.8	580
27	The Scleroderma Patient-centered Intervention Network Self-Management (SPIN-SELF) Program: protocol for a two-arm parallel partially nested randomized controlled feasibility trial with progression to full-scale trial. Trials, 2021, 22, 856.	0.7	4
28	Systematic Review of Economic Evaluations of Cycling Versus Swapping Medications in Patients With Rheumatoid Arthritis After Failure to Respond to Tumor Necrosis Factor Inhibitors. Arthritis Care and Research, 2020, 72, 343-352.	1.5	4
29	Systematic Review of Recommendations on the Use of Diseaseâ€Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Cancer. Arthritis Care and Research, 2020, 72, 309-318.	1.5	20
30	Evidence that Swimming May Be Protective of Knee Osteoarthritis: Data from the Osteoarthritis Initiative. PM and R, 2020, 12, 529-537.	0.9	4
31	Comparison of multimedia and printed patient education tools for patients with osteoporosis: a 6-month randomized controlled trial. Osteoporosis International, 2020, 31, 857-866.	1.3	13
32	Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancer. Clinical Rheumatology, 2020, 39, 787-794.	1.0	7
33	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. Supportive Care in Cancer, 2020, 28, 6119-6128.	1.0	20
34	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities. Supportive Care in Cancer, 2020, 28, 6175-6181.	1.0	15
35	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. Supportive Care in Cancer, 2020, 28, 6159-6173.	1.0	11
36	Psychosocial Determinants of Total Knee Arthroplasty Outcomes Two Years After Surgery. ACR Open Rheumatology, 2020, 2, 573-581.	0.9	6

#	Article	IF	CITATIONS
37	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. Supportive Care in Cancer, 2020, 28, 6129-6143.	1.0	28
38	Cancer immunotherapy–related adverse events: causes and challenges. Supportive Care in Cancer, 2020, 28, 6111-6117.	1.0	22
39	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity. Supportive Care in Cancer, 2020, 28, 6145-6157.	1.0	14
40	Cervical Cancer Screening in Women with Systemic Lupus Erythematosus. Arthritis Care and Research, 2020, 73, 1796-1803.	1.5	5
41	Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapy. Clinical Rheumatology, 2020, 39, 2943-2950.	1.0	8
42	Reply. Arthritis Care and Research, 2020, 72, 1828-1829.	1.5	0
43	Immune-related adverse events of checkpoint inhibitors. Nature Reviews Disease Primers, 2020, 6, 38.	18.1	684
44	Survival in older women with early stage breast cancer receiving lowâ€dose bisphosphonates or denosumab. Cancer, 2020, 126, 3929-3938.	2.0	10
45	Cancer and Rheumatoid Arthritis. Rheumatic Disease Clinics of North America, 2020, 46, 445-462.	0.8	19
46	Association of Serum Folate Levels With Cardiovascular Mortality Among Adults With Rheumatoid Arthritis. JAMA Network Open, 2020, 3, e200100.	2.8	13
47	Knowledge, beliefs, and concerns about bone health from a systematic review and metasynthesis of qualitative studies. PLoS ONE, 2020, 15, e0227765.	1.1	17
48	Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumors. Blood Advances, 2020, 4, 1746-1755.	2.5	17
49	Bone Mineral Density at the Time of Initiating Aromatase Inhibitor Therapy Is Associated With Decreased Fractures in Women With Breast Cancer. Journal of Bone and Mineral Research, 2020, 36, 861-871.	3.1	9
50	Interactions and perceptions of patients with rheumatoid arthritis participating in an online support group. Clinical Rheumatology, 2020, 39, 1775-1782.	1.0	13
51	The Scleroderma Patient-Centered Intervention Network Self-Management Program: Protocol for a Randomized Feasibility Trial. JMIR Research Protocols, 2020, 9, e16799.	0.5	7
52	Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Seminars in Arthritis and Rheumatism, 2019, 48, 736-740.	1.6	90
53	Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial). BMJ Open, 2019. 9. e028517.	0.8	19
54	ls Immune Checkpoint Inhibitor Treatment an Option for Patients With Rheumatic Diseases and Cancer?. Arthritis and Rheumatology, 2019, 71, 1971-1973.	2.9	4

#	Article	IF	CITATIONS
55	Realâ€World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis. ACR Open Rheumatology, 2019, 1, 560-570.	0.9	11
56	A comprehensive scoping review to identify standards for the development of health information resources on the internet. PLoS ONE, 2019, 14, e0218342.	1.1	21
57	Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare. , 2019, 7, 126.		17
58	Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials. Journal of Rheumatology, 2019, 46, 1173-1178.	1.0	6
59	Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. , 2019, 7, 106.		203
60	Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis. Journal of Rheumatology, 2019, 46, 1164-1167.	1.0	7
61	Digital Patient Education and Decision Aids. Rheumatic Disease Clinics of North America, 2019, 45, 245-256.	0.8	28
62	Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. , 2019, 7, 319.		164
63	Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy. Rheumatology, 2019, 58, vii40-vii48.	0.9	49
64	Arthritis risk with immune checkpoint inhibitor therapy for cancer. Current Opinion in Rheumatology, 2019, 31, 293-299.	2.0	36
65	Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologists. Expert Review of Clinical Immunology, 2019, 15, 211-213.	1.3	5
66	Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. , 2019, 7, 2.		213
67	Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials. Seminars in Arthritis and Rheumatism, 2019, 48, 958-966.	1.6	9
68	Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR). Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 114-122.	0.4	19
69	Assessing information needs and use of online resources for disease self-management in patients with rheumatoid arthritis: a qualitative study. Clinical Rheumatology, 2018, 37, 1791-1797.	1.0	33
70	Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol. Trials, 2018, 19, 204.	0.7	23
71	Running does not increase symptoms or structural progression in people with knee osteoarthritis: data from the osteoarthritis initiative. Clinical Rheumatology, 2018, 37, 2497-2504.	1.0	38
72	Low Rate of Cervical Cancer Screening among Women with Hematologic Malignancies after Stem Cell Transplant. Biology of Blood and Marrow Transplantation, 2018, 24, 1094-1098.	2.0	11

#	Article	IF	CITATIONS
73	Development and Pilot Testing of Multimedia Patient Education Tools for Patients With Knee Osteoarthritis, Osteoporosis, and Rheumatoid Arthritis. Arthritis Care and Research, 2018, 70, 213-220.	1.5	28
74	Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Investigational New Drugs, 2018, 36, 601-607.	1.2	90
75	Treating Early Undifferentiated Arthritis: A Systematic Review and Metaâ€Analysis of Direct and Indirect Trial Evidence. Arthritis Care and Research, 2018, 70, 1355-1365.	1.5	18
76	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Investigational New Drugs, 2018, 36, 638-646.	1.2	149
77	Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study. Journal of Clinical Oncology, 2018, 36, 959-967.	0.8	18
78	Readmission Patterns After GI Cancer Hospitalizations: The Medical Versus Surgical Patient. Journal of Oncology Practice, 2018, 14, e137-e148.	2.5	9
79	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2018, 36, 1714-1768.	0.8	2,691
80	Passive transfer of anti-HBc after intravenous immunoglobulin administration in patients with cancer: a retrospective chart review. Lancet Haematology,the, 2018, 5, e474-e478.	2.2	20
81	Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease. Annals of Internal Medicine, 2018, 168, 121.	2.0	341
82	The outcome of checkpoint inhibitor therapy in patients with cancer and solid organ transplant: A systematic review of the literature Journal of Clinical Oncology, 2018, 36, 41-41.	0.8	7
83	Hepatotoxicity in advanced cancer patients receiving immune-based cancer treatment Journal of Clinical Oncology, 2018, 36, 67-67.	0.8	0
84	Review: Immuneâ€Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer. Arthritis and Rheumatology, 2017, 69, 687-699.	2.9	101
85	Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. The Cochrane Library, 2017, 2017, CD012591.	1.5	44
86	Systematic review of the methodological quality of controlled trials evaluating Chinese herbal medicine in patients with rheumatoid arthritis. BMJ Open, 2017, 7, e013242.	0.8	18
87	Prospective cohort study of cancer patients diagnosed with incidental venous thromboembolism on routine computed tomography scans. Supportive Care in Cancer, 2017, 25, 1571-1577.	1.0	6
88	Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. The Cochrane Library, 2017, 5, CD012657.	1.5	47
89	Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report. Journal of Rheumatology, 2017, 44, 1894-1898.	1.0	12
90	Impact of the timing of hepatitis B virus identification and anti–hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. Cancer, 2017, 123, 3367-3376.	2.0	13

#	Article	IF	CITATIONS
91	Systolic and pulse pressure associate with incident knee osteoarthritis: data from the Osteoarthritis Initiative. Clinical Rheumatology, 2017, 36, 2121-2128.	1.0	24
92	Adverse Events in Cancer Immunotherapy. Advances in Experimental Medicine and Biology, 2017, 995, 155-174.	0.8	45
93	Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series. Annals of the Rheumatic Diseases, 2017, 76, 2061-2064.	0.5	141
94	Online Educational Tool to Promote Bone Health in Cancer Survivors. Journal of Health Communication, 2017, 22, 808-817.	1.2	7
95	Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group. Journal of Rheumatology, 2017, 44, 1916-1919.	1.0	11
96	Impact of Rheumatoid Arthritis on the Mortality of Elderly Patients Who Develop Cancer: A Populationâ€Based Study. Arthritis Care and Research, 2017, 69, 75-83.	1.5	26
97	Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials. Seminars in Arthritis and Rheumatism, 2017, 46, 699-708.	1.6	19
98	Marine Oil Supplements for Arthritis Pain: A Systematic Review and Meta-Analysis of Randomized Trials. Nutrients, 2017, 9, 42.	1.7	90
99	Training in patient-centered outcomes research for specific researcher communities. Journal of Clinical and Translational Science, 2017, 1, 278-284.	0.3	1
100	Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. PLoS ONE, 2016, 11, e0160221.	1.1	373
101	Validation of the Selfâ€Efficacy for Managing Chronic Disease Scale: A Scleroderma Patientâ€Centered Intervention Network Cohort Study. Arthritis Care and Research, 2016, 68, 1195-1200.	1.5	31
102	Systematic review of case reports of antiphospholipid syndrome following infection. Lupus, 2016, 25, 1520-1531.	0.8	105
103	Patients' expectations about total knee arthroplasty outcomes. Health Expectations, 2016, 19, 299-308.	1.1	27
104	Effect of Body Mass Index and Psychosocial Traits on Total Knee Replacement Costs in Patients with Osteoarthritis. Journal of Rheumatology, 2016, 43, 1600-1606.	1.0	11
105	Assessing information needs on bone health in cancer survivors. Journal of Cancer Survivorship, 2016, 10, 480-488.	1.5	9
106	Improving treatment adherence in patients with rheumatoid arthritis: what are the options?. International Journal of Clinical Rheumatology, 2015, 10, 345-356.	0.3	66
107	HIV Testing in Patients With Cancer at the Initiation of Therapy at a Large US Comprehensive Cancer Center. Journal of Oncology Practice, 2015, 11, 384-390.	2.5	17
108	Patterns and Predictors of Unplanned Hospitalization in a Population-Based Cohort of Elderly Patients With GI Cancer. Journal of Clinical Oncology, 2014, 32, 3527-3533.	0.8	72

#	Article	IF	CITATIONS
109	Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy. Supportive Care in Cancer, 2014, 22, 537-544.	1.0	11
110	Hepatitis C Virus Screening in Patients With Cancer Receiving Chemotherapy. Journal of Oncology Practice, 2014, 10, e167-e174.	2.5	19
111	Costâ€Effectiveness of Total Knee Replacement: A Prospective Cohort Study. Arthritis Care and Research, 2014, 66, 592-599.	1.5	62
112	Methotrexate for treating rheumatoid arthritis. The Cochrane Library, 2014, 2014, CD000957.	1.5	134
113	The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. BMJ Open, 2013, 3, e003563.	0.8	104
114	Electronic Monitoring of Oral Therapies in Ethnically Diverse and Economically Disadvantaged Patients With Rheumatoid Arthritis: Consequences of Low Adherence. Arthritis and Rheumatism, 2013, 65, 1421-1429.	6.7	92
115	Lipid Paradox in Rheumatoid Arthritis: Changes With Rheumatoid Arthritis Therapies. Current Rheumatology Reports, 2012, 14, 428-437.	2.1	37
116	Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. Supportive Care in Cancer, 2012, 20, 2985-2998.	1.0	90
117	Identification of rheumatoid arthritis patients using an administrative database: A Veterans Affairs study. Arthritis Care and Research, 2012, 64, 1490-1496.	1.5	55
118	Acupuncture in the Treatment of Rheumatic Diseases. Current Rheumatology Reports, 2012, 14, 589-597.	2.1	47
119	2012 Update of the 2008 American College of Rheumatology recommendations for the use of diseaseâ€modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care and Research, 2012, 64, 625-639.	1.5	1,413
120	Impact of educational and patient decision aids on decisional conflict associated with total knee arthroplasty. Arthritis Care and Research, 2012, 64, 229-237.	1.5	76
121	Problems in transition and quality of care: perspectives of breast cancer survivors. Supportive Care in Cancer, 2011, 19, 1921-1929.	1.0	44
122	Acetaminophen overdose: a little recognized public health threat. Pharmacoepidemiology and Drug Safety, 2011, 20, 827-829.	0.9	15
123	Psychosocial determinants of outcomes in knee replacement. Annals of the Rheumatic Diseases, 2011, 70, 1775-1781.	0.5	139
124	A Qualitative Analysis of Decision-Making for Total Knee Replacement in Patients With Osteoarthritis. Journal of Clinical Rheumatology, 2010, 16, 158-163.	0.5	56
125	A systematic review of the effect of TNF-α antagonists on lipid profiles in patients with rheumatoid arthritis. Clinical Rheumatology, 2010, 29, 947-955.	1.0	55
126	A randomized controlled trial of acupuncture for osteoarthritis of the knee: Effects of patientâ€provider communication. Arthritis Care and Research, 2010, 62, 1229-1236.	1.5	156

#	Article	IF	CITATIONS
127	Comorbidities and Overall Survival In Myelodysplastic Syndromes (MDS): Development of a Prognostic Model Incorporating IPSS and Age with ACE-27 Comorbidity Index. Blood, 2010, 116, 605-605.	0.6	1
128	Comorbidities and Myelodysplatic Syndromes Blood, 2009, 114, 2789-2789.	0.6	3
129	Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clinical Rheumatology, 2008, 27, 883-889.	1.0	110
130	Quality appraisal of clinical practice guidelines and consensus statements on the use of biologic agents in rheumatoid arthritis: A systematic review. Arthritis and Rheumatism, 2008, 59, 1625-1638.	6.7	40
131	Disease and symptom burden in systemic sclerosis: a patient perspective. Journal of Rheumatology, 2007, 34, 1718-26.	1.0	77
132	Initiation of disease-modifying antirheumatic drug therapy in minority and disadvantaged patients with rheumatoid arthritis. Journal of Rheumatology, 2007, 34, 2400-7.	1.0	16
133	Ethnic Variation in Knee Replacement. Archives of Internal Medicine, 2005, 165, 1117.	4.3	137
134	Self Report Co-Morbidity and Health Related Quality of Life – A Comparison with Record Based Co-Morbidity Measures. Social Indicators Research, 2004, 66, 213-228.	1.4	17
135	Determinants of Function After Total Knee Arthroplasty. Physical Therapy, 2003, 83, 696-706.	1.1	223
136	Regulatory issues and economic efficiency. Journal of rheumatology Supplement, The, 2003, 68, 5-7.	2.2	2
137	Attitudes of Terminally III Cancer Patients About Euthanasia and Assisted Suicide: Predominance of Psychosocial Determinants and Beliefs Over Symptom Distress and Subsequent Survival. Journal of Clinical Oncology, 2002, 20, 2134-2141.	0.8	84
138	Is there a role for ginger in the treatment of osteoarthritis?. Arthritis and Rheumatism, 2001, 44, 2461-2462.	6.7	19
139	Modeling changes in health perception following hip fracture. Quality of Life Research, 2001, 10, 651-659.	1.5	8
140	Mortality and Institutionalization Following Hip Fracture. Journal of the American Geriatrics Society, 2000, 48, 283-288.	1.3	211
141	Cyclophosphamide for treating rheumatoid arthritis. The Cochrane Library, 2000, , .	1.5	16
142	Calcium and vitamin D for corticosteroid-induced osteoporosis. The Cochrane Library, 1998, , CD000952.	1.5	93